Investments in Research and Development for Supplemental Drug Indications—Implications for Drug Price Negotiations
Bibliographic Data
| ID | 15808264 |
|---|---|
| Authors | Kerstin Noëlle Vokinger (0000-0002-6997-7384, University of Zurich, corresponding author), Gellért Perényi (University of Zurich), Olivier J Wouters (0000-0002-2514-476X, London School of Economics and Political Science) |
| Year | 2023 |
| Volume | 4 |
| Issue | 9 |
| Pages | e232798-e232798 |
| Publication date | 2023-09-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | JAMA Health Forum (JOURNAL) |
| Journal identifiers | ISSN: 2689-0186 • E-ISSN: 2689-0186 |
| Publisher | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/jamahealthforum.2023.2798 |
| PMID | 37656469 |
| OpenAlex | W4386347255 |
| Language | EN |
| References cited | 5 |
This Viewpoint compares the research and development costs for a drug’s first indication with supplemental indications to demonstrate that the cost of approval for supplemental indications may be substantially lower
Business · Drug · Drug development · Drug prices · Economics · Intensive care medicine · Negotiation · Political science · Public economics · Risk analysis (engineering · Health Systems, Economic Evaluations, Quality of Life · Law · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical studies and practices · Pharmacology
| Citation velocity | historical |
|---|---|
| Highly cited | No |